SANDU PHARMACEUTICALS LTD.

Sandu Pharmaceuticals Limited has informed the stock exchanges about a change in the name of one of its directors. Dr. Neeti Madan Kapre, a Non-Executive Independent Director, will now be known as Dr. Neeti Gupta following her marriage. The company confirmed that this is solely a name change and there is no alteration in her designation, directorship, or Director Identification Number (DIN). The change is supported by documentary evidence and has been recorded by the company.

Sandu Pharmaceuticals Ltd has issued an intimation to holders of physical securities, urging them to furnish their Permanent Account Number (PAN) and Know Your Customer (KYC) details as per SEBI Master Circular dated June 23, 2025. This is a mandatory requirement for updating records with the Registrar and Transfer Agent, MUFG Intime India Private Limited. Failure to update these details, including PAN, contact information, mobile number, and bank account details, will result in dividends being paid only through electronic mode from April 01, 2024. The company has also highlighted a special window for re-lodgement of transfer deeds, open from February 05, 2026, to February 04, 2027, during which securities will be issued only in demat mode. Forms and details are available on the company and RTA websites.

Sandu Pharmaceuticals Ltd has announced the closure of its trading window for the quarter ended September 30, 2026. The window will be closed from October 1, 2026, until 48 hours after the declaration of the financial results for the quarter. This action is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code. The restriction applies to Directors, KMPs, Promoters, Designated Persons, and their immediate relatives. The date for the Board Meeting to approve the unaudited financial results will be intimated subsequently.

Sandu Pharmaceuticals Ltd announced significant management changes following its 41st Annual General Meeting held on September 11, 2026. Shri Balram Viswanathan has been redesignated as Chairman and Managing Director for a term of three years. Concurrently, Dr. Smt. Neeti Kapre has been appointed as a Non-Executive Independent Director for a term of five years. These appointments were approved by the company's members through requisite resolutions.

Sandu Pharmaceuticals Ltd announced the appointment of M/s. Dave & Dave, Chartered Accountants, as its new Statutory Auditors. This appointment was approved by the shareholders at the company's 41st Annual General Meeting held on September 11, 2026. The new auditors will serve for a term of five consecutive years, from the conclusion of the 41st AGM until the conclusion of the 46th AGM in 2031. This change follows the completion of the tenure of the previous auditors, M/s Dileep and Prithvi, Chartered Accountants. The company stated that the transition is in accordance with the Companies Act, 2013, and the outgoing auditors raised no concerns.

Sandu Pharmaceuticals Ltd is notifying shareholders whose email IDs are not registered with the company or RTA about the availability of the Annual Report for FY 2026-27. The 41st AGM is scheduled for September 11, 2026. Shareholders without registered emails will receive a letter with a weblink to access the full annual report. This communication also serves as a reminder for shareholders holding physical securities to update KYC details and dematerialize their holdings as per SEBI regulations, with implications for payments like dividends if details are not updated by April 17, 2024.

Sandu Pharmaceuticals Ltd has announced its 41st Annual General Meeting (AGM) to be held on Friday, September 11, 2026, at 4:30 PM IST. The meeting will be conducted through Video Conferencing or other audio-visual means. Key agenda items include the adoption of the audited standalone financial statements for the financial year ended March 31, 2026, reappointment of Smt Jayshree Sandu as a Director, declaration of a dividend of ₹1.00 per equity share (10%), and appointment of M/s. Dave & Dave as Statutory Auditors for a term of five years. The company has also initiated the process of sending the AGM notice electronically to shareholders and has uploaded the Annual Report 2025-26 on its website.

Sandu Pharmaceuticals Limited has released its 41st Annual Report for the financial year 2025-26, coinciding with the notice for its 41st Annual General Meeting (AGM) scheduled for September 11, 2026. The AGM will be conducted via Video Conferencing (VC/OAVM). The report highlights a revenue of ₹6,993.45 lakhs and a notable 23.187% increase in net profit, attributed to operational efficiencies and cost management. The company emphasizes its commitment to Ayurvedic traditions, innovation in product development, and sustainability initiatives, including eco-friendly practices and community welfare. Sandu Pharmaceuticals is investing in R&D, infrastructure modernization, and brand building to drive future growth and long-term stakeholder value.

Sandu Pharmaceuticals Ltd has filed a statement of deviation and utilization of funds for the quarter ended June 30, 2026. The company reported on the utilization of funds raised through a preferential issue of equity shares (private placement). For the first tranche, ₹2,63,79,653 was raised on March 31, 2021, and for the second tranche, ₹1,38,05,408 was raised on February 28, 2022. In both instances, the funds raised were fully utilized as per the original objects, which included revamping capital machinery, developing marketing infrastructure, civil work, purchasing plant and machinery, working capital, and general business enhancement. The Audit Committee has reviewed and approved the statement, with no comments from the auditors.

Sandu Pharmaceuticals Ltd announced the appointment of M/s Dave & Dave Chartered Accountants as its statutory auditor for a five-year term, subject to shareholder approval. The Board of Directors, based on the Audit Committee's recommendation, approved the appointment. The firm, established in 1989, has extensive experience and is not related to any company directors or key personnel. The company also approved its unaudited standalone financial results for the quarter ended June 30, 2026, along with various reports for the financial year ended March 31, 2026. The 41st Annual General Meeting is scheduled for September 11, 2026, and a record date of September 4, 2026, has been set for dividend eligibility.